SRGN aggravates cerebral ischemia/reperfusion injury by inducing SLC7A11 depletion and excessive mitophagy-dependent neuronal death
This study demonstrates that Serglycin (SRGN) exacerbates cerebral ischemia/reperfusion injury by promoting SLC7A11 degradation and excessive mitophagy, identifying circulating SRGN as a potential biomarker and RBC-EVs@siSRGN as an effective targeted therapeutic strategy for ischemic stroke.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a blood clot blocks a vessel in the brain, the immediate threat is the lack of oxygen. However, once medical teams successfully clear that blockage and restore blood flow, a second, often more damaging wave of injury begins. This phenomenon, known as reperfusion injury, occurs because the sudden return of oxygen triggers a chaotic chemical reaction inside brain cells. The cells, which have been starved of oxygen, struggle to handle the flood of new energy. This struggle produces a toxic buildup of unstable molecules that damage the cell's internal machinery. Among the most critical components of this machinery are the mitochondria, the tiny power plants that generate energy for the cell. Normally, cells have a cleanup crew that removes damaged mitochondria to keep the system running smoothly. But in the chaos of a stroke, this cleanup process can go into overdrive, destroying healthy power plants along with the broken ones, leading to the death of the brain cell. Understanding exactly what triggers this destructive overreaction is essential for finding ways to stop it.
Researchers at Wujin Hospital and Jiangsu University in China have identified a specific protein that acts as a trigger for this cellular self-destruction during stroke recovery. They focused on a molecule called serglycin, or SRGN, which is naturally found in the blood and tissues. By examining blood samples from patients who had suffered an acute stroke, the team discovered that levels of this protein were significantly higher in those patients compared to healthy individuals. This finding suggested that SRGN might be a useful marker for detecting the severity of a stroke. To understand why these levels were so high, the scientists turned to laboratory models. They exposed human brain cells to conditions that mimic a stroke—depriving them of oxygen and glucose, then reintroducing them—and observed that the cells began producing large amounts of SRGN as they were damaged.
The study revealed that this surge in SRGN does not just happen alongside the injury; it actively makes the damage worse. The researchers found that high levels of SRGN interfere with a protective protein called SLC7A11. This protective protein acts like a shield, helping the cell maintain a balance of antioxidants and preventing the toxic buildup of unstable molecules. SRGN binds directly to SLC7A11 and marks it for destruction, causing the cell to break it down much faster than usual. Without enough of this protective shield, the brain cell's internal environment becomes toxic. This toxicity sends a false signal to the cell's cleanup crew, instructing it to start eating away at the mitochondria. Instead of a controlled cleanup, the cell enters a state of excessive self-consumption, destroying its own energy sources and dying in the process.
To prove that this chain of events was the cause of the damage, the team performed a series of experiments where they silenced the gene responsible for making SRGN. When they prevented the brain cells from producing this protein, the protective SLC7A11 remained stable, the toxic buildup was avoided, and the cells survived the simulated stroke much better. They further confirmed this by using a drug to block the protective protein; when the protection was removed, the cells died even if SRGN was absent, proving that the loss of this specific shield was the key step in the destruction. The researchers also tested a different approach to see if they could stop the damage by targeting SRGN directly. They developed a delivery system using tiny bubbles made from the membranes of red blood cells. These bubbles were loaded with a genetic tool designed to silence the SRGN gene. Because these bubbles are made from blood cells, they can travel through the bloodstream and cross the natural barrier that protects the brain, delivering their cargo directly to the injured tissue.
In mice that had suffered a stroke, these red blood cell bubbles successfully reached the damaged area of the brain. Once there, they silenced the SRGN gene, which allowed the protective protein to recover. The treated mice showed significantly smaller areas of brain damage, less inflammation, and better recovery of movement and function compared to untreated mice. The study concludes that SRGN is a critical driver of brain cell death after a stroke because it dismantles the cell's antioxidant defenses, leading to a runaway destruction of mitochondria. While the research was conducted in cells and mice, the findings suggest that measuring SRGN in the blood could help doctors assess stroke severity, and that blocking this protein might offer a new way to protect the brain during the critical hours after a stroke is treated.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.